Western medicine prohibits opening traditional Chinese medicine in the buffer period when the Chinese patent medicine enterprise mutiny is going on

 Western medicine prohibits opening traditional Chinese medicine in the buffer period when the Chinese patent medicine enterprise mutiny is going on

General practitioners and rural doctors in primary medical institutions can prescribe common and frequently-occurring Chinese patent medicines, and they can also continue to use long-term prescriptions of Chinese patent medicines prescribed by Chinese doctors. At the same time, after not less than one years systematic study of TCM professional knowledge and examination of qualified, in accordance with the basic principles of TCM clinical differentiation and treatment, Chinese patent medicine prescriptions can be issued.

In July before, the State Health and Health Commission clearly put forward restrictions on prescriptions of traditional Chinese medicine for Western medicine when publishing the first batch of catalogues to monitor rational use of drugs. When the National Medical Insurance Bureau promulgated the national medical insurance catalogue on August 20, it also restricted the payment of traditional Chinese medicine prescriptions for Western medicine. This time Shandong allowed doctors at the grass-roots level to prescribe some Chinese patent medicines, which could be understood as a buffer against the total prohibition of Western medicine prescribing Chinese patent medicines.

According to the analysis of a medical analyst from a medium-sized securities firm in East China to the 21st century economic reporters, since this year, the monitoring of key drug catalogues has been a year of contraction and pressure for Chinese patent medicine enterprises, whether it is purchasing with quantity, checking through accounts, or adjusting medical insurance catalogues. However, the most important impact of these policies on the follow-up industry should be to prohibit Western medicine from prescribing Chinese patent medicines.

Combating the Abuse of Traditional Chinese Medicine

For a long time, relying on Western medicine to develop some chicken ribs of Chinese patent medicine has become a persistent disease in the industry.

70% of Chinese patent medicines are prescribed by Western medicine, and the actual situation of some hospitals is even more overheated than this figure. Whether western medicine can prescribe traditional Chinese medicine has been controversial in the industry.

Why do western medicine prefer to prescribe traditional Chinese medicine? Traditional Chinese medicine often makes patients pay a wrong account in their confusion, and the high rebate of traditional Chinese medicine also brings benefits to Western medicine.

Traditional Chinese medicine prescription granules are granules made from single Chinese medicine decoction pieces by extraction and concentration for clinical prescription of traditional Chinese medicine. Formerly known as single herbal concentrate granules, commercial names and folk names also include Decoction-free Chinese herbal pieces, new pieces, refined pieces, beverage-based pieces, scientific Chinese medicines, etc. It is a new type of prescription medicine, which is made from traditional Chinese medicine pieces and processed through a series of production processes.

Back to the level of interests, since the implementation of zero price difference of drugs by the state, Chinese herbal pieces have been excluded. As Chinese herbal pieces have become the only additive medicine in the medical insurance drug catalogue, hospitals have been carrying out Chinese Herbal Pieces business in full swing.

The scale of Chinese formula granule market increased from 1.9 billion yuan in 2010 to 7.8 billion yuan in 2014, with a compound growth rate of 40.7%, and to 12.3 billion yuan in 2016. Industry insiders said that in 2018, the industry of traditional Chinese medicine formula granule should be around 20 billion yuan, an increase of 30% over the same period of last year. The surge of this market is due to the fact that Chinese medicine prescription granules are attributable to the Chinese medicine decoction pieces, which to some extent occupies the medical insurance resources.

A licensed pharmacist of a third-class hospital in Guangzhou pointed out to the reporter of economic report in the 21st century: For a long time, it has become a habit for western medicine to issue traditional Chinese medicine. Not only western medicine, but also a large number of pharmacists who hold western medicine licensed pharmacists are in the process of issuing traditional Chinese medicine. Few of them will take the examination for practicing traditional Chinese medicine. Pharmacist certificate. When the policy came out in July this year, the pharmaceutical industry was generally regarded as a signal to crack down on the abuse of Chinese patent medicines. Once the policy is fully implemented, it will inevitably bring about considerable impact on Chinese patent medicine enterprises.

Buffer period mutiny

For Chinese patent medicine enterprises, this year has also experienced several waves. On June 4, the Ministry of Finance organized an accounting inspection of 77 pharmaceutical enterprises, of which 33 were Chinese medicine manufacturers, accounting for more than chemical and biological pharmaceutical enterprises. During the inspection, the National Medical Security Bureau followed up the whole process. The State Medical Insurance Bureau is responsible for formulating the catalogue of medical insurance and the standard of medical insurance payment. On August 21, the National Medical Security Bureau announced the 2009 edition of the Medical Insurance Catalogue, which increased the number of Chinese patent medicines to 1321, which was in line with 1322 western medicines.

On July 1, the Health and Health Commission published the first list of national key drugs to monitor rational drug use. Twenty drugs, including calf serum deproteinization, mouse nerve growth factor, vinpocetine and ribonucleic acid, were monitored and kicked out of the list.

In addition, in the past few years, the performance of Chinese medicine enterprises has declined to a normal level. Secondly, policy changes such as two-vote system, medical insurance control fee, proportion of controlled medicines and adjustment of auxiliary catalogue medicines have become the most important factors. In addition, some doctors and patients increasingly disapprove of traditional Chinese medicine. Traditional Chinese medicine enterprises have to think about the direction and path of transformation.

Traditional Chinese medicine enterprises have been seeking new profit growth points, through the involvement of innovative drug research and development to explore new track.

Industry shuffling is irreversible. In the past, the development of traditional Chinese medicine enterprises was mainly through mergers and acquisitions. In the future, OTC may compete more intensely. For R&D, due to the special attributes of traditional Chinese medicine, the transformation of traditional Chinese medicine enterprises into biopharmaceutical R&D pipeline reserve has become a certain trend.

But there are also insiders to the 21st century economic report reporter frankly, although it seems that traditional Chinese medicine enterprises have become a trend to muddle innovative drugs, but for traditional Chinese medicine enterprises, due to the great differences in the basis, Chinese patent medicine enterprises want to achieve leapfrog development, it is particularly important to provide scientific and data to prove the efficacy. Enterprises should reevaluate the safety and effectiveness of existing varieties in accordance with the clinical guidelines of CDE (Drug Evaluation Center of the State Drug Administration). Drug clinical comprehensive evaluation system follows the six principles of safety, effectiveness, compliance, innovation, economy and sustainability. Only when the Chinese patent medicine has passed the national comprehensive drug clinical evaluation system can it be recognized by medical insurance. However, it is very difficult for Chinese medicine enterprises to make breakthroughs in the field of innovative drugs. The plot of OTC breakthroughs and changes to retail channels may be more direct.

Source: Yang Qian_NF4425, Responsible Editor of Economic Report in the 21st Century